Seizure susceptibility in immature brain due to lack of COX-2-induced PGF2α

Jee-In Chung1, A Young Kim, Soo Hwan Lee

  • 1Department of Physiology, Ajou University School of Medicine, Suwon, Republic of Korea; Chronic Inflammatory Disease Research Center, Ajou University School of Medicine, Suwon, Republic of Korea.

Experimental Neurology
|September 6, 2013
PubMed

Insights

Immature brains are more susceptible to seizures due to low cyclooxygenase (COX) activity and prostaglandin (PG) F2α deficiency. Restoring PGF2α levels can reduce seizure severity in young mice.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Pharmacology

Background:

  • The immature brain exhibits heightened seizure susceptibility, a mechanism not fully understood.
  • Prostaglandin (PG) F2α, produced by cyclooxygenase (COX), acts as an anticonvulsant in adult brains.
  • Non-steroidal anti-inflammatory drugs are not recommended for febrile seizures in children.

Purpose of the Study:

  • To investigate the role of cyclooxygenase (COX) activity in early-life seizure susceptibility.
  • To determine if prostaglandin (PG) F2α deficiency contributes to immature brain vulnerability to seizures.

Main Methods:

  • Comparison of kainic acid (KA)-induced seizure activity in immature (postnatal day 9) and mature (postnatal day 35) mice.
  • Assessment of COX-2 expression and PGF2α levels in developing mouse brains.
  • Evaluation of indomethacin (COX inhibitor) effects on seizure activity.
  • Administration of PGF2α to immature mice to assess its anticonvulsant effects.

Main Results:

  • Immature mice showed increased severity and duration of KA-induced seizures compared to mature mice.
  • Indomethacin did not affect seizures in immature mice but aggravated them in mature mice.
  • Immature brains had low basal and KA-induced COX-2 expression and PGF2α release.
  • COX expression and activity increased with age during brain development.
  • PGF2α administration reduced seizure activity and mortality in immature mice.

Conclusions:

  • Low cyclooxygenase (COX) activity and resultant prostaglandin (PG) F2α deficiency are key factors in immature brain seizure susceptibility.
  • Age-dependent changes in COX expression and activity are critical for brain maturation and seizure resistance.
  • Targeting the COX-PGF2α pathway may offer therapeutic strategies for early-life seizures.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...